Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vincristine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 0.97 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 0.97 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 0.97 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 0.97 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 0.97 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 0.97 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 0.97 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 0.97 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 0.97 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 0.97 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 0.97 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 0.97 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 0.97 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 0.97 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vincristine SCHEMBL4640472 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4709855 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL2946485 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL18398051 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL3710 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL29519343 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL29895946 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4742962 | 0.99 | MAPT (0.98) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL18402663 | 0.98 | LMNA (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4769981 | 0.98 | LMNA (1.00) | MAPTMEN1KMT2ALMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 46750 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260125428-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | UNIV CONNECTICUT (US) | 2026-05-07 | — | — | US | claimed |
| EP-4735116-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-3856736-B1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| EP-4727959-A1 | BIOMARKERS AND METHODS OF TREATMENT OF FOLLICULAR LYMPHOMA | Bristol-Myers Squibb Company (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| EP-4722240-A1 | COMBINATION OF ANTIBODIES, OR ANTIGEN-BINDING FRAGMENTS THEREOF, FOR THE TREATMENT OF CANCERS AND COMPOSITIONS THEREOF | Xenothera (FR) | 2026-04-08 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-0335966-A4 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS. | MATRIX PHARMA INC (US) | 1990-02-20 | — | — | EP | claimed |
| US-4883805-A | LEUKEMIA TREATMENT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1989-11-28 | — | — | US | claimed |
| EP-0335966-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-10-11 | — | — | EP | claimed |
| WO-1989002734-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-04-06 | — | — | WO | claimed |
| EP-0298192-A1 | Stable, injectable solutions of vincristine salts | Teva Pharmaceutical Industries Limited (IL) | 1989-01-11 | — | — | EP | claimed |
| US-4711782-A | Prolonged release microcapsules and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-12-08 | — | — | US | claimed |
| US-4619935-A | Stable oncolytic formulations | ELI LILLY AND COMPANY (US) | 1986-10-28 | — | — | US | claimed |
| EP-0120907-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | Aston Molecules Limited (GB) | 1984-10-10 | — | — | EP | claimed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | claimed |
| EP-0010964-A1 | Ravidomycin, process of preparation and pharmaceutical compositions containing same | AYERST, MCKENNA AND HARRISON INC. (CA) | 1980-05-14 | — | — | EP | claimed |